Option chain shows key data for Eupraxia Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Eupraxia Pharmaceuticals.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock, Option Chain

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

EPRX

IDYA

SNDK

This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

xr:d:DAFj0FUZspA:2,j:5351515556,t:23052408

Movers

AKTS

BNED

BRLS

CJET

CRKN

EDBL

LFST

LMFA

MBIO

MGOL

MGRX

RZLT

SINT

URBN

VRPX

VSAT

VSME

XYLO

Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Trading Ideas

AEHL

ALLR

AUUD

BCAN

BRCC

CCTG

DXYZ

ESPR

FAAS

FLGC

GLMD

LGVN

MDIA

MSTR

NCPL

RELI

XXII

ZOOZ

Shares of  Esperion Therapeutics, Inc.  (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc Ordinary Shares

Press Releases

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Earnings

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Health Care

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

"Bear-Pit Session" Highlights Peterson Capital's Canada Growth Conference in Montreal

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Comments

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell